Ceregene Inc., of San Diego, reported additional efficacy data from a secondary analysis of its Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin to treat Parkinson's disease

Elcelyx Therapeutics Inc., of San Diego, said it is enrolling patients with Type II diabetes in a Phase IIb trial of NewMet, a delayed-release formulation of generic metformin...Tracon Pharmaceuticals Inc., of San Diego, said it initiated two randomized Phase IIb studies to evaluate TRC105 in combination with bevacizumab (Avastin) in metastatic kidney cancer and recurrent glioblastoma multiforme

Prometheus Laboratories Inc., of San Diego, said PROCLIVITY 01, a multicenter study of Proleukin (High Dose Interleukin-2 [HD IL-2])1 plus vemurafenib therapy in patients with BRAF V600 mutation-positive metastatic melanoma (mM) is enrolling patients

Metreleptin was part of the alliance between BMS and AstraZeneca plc, of London, to buy out Amylin Pharmaceuticals Inc., of San Diego, which had metreleptin among its assets. (See BioWorld Today, July 5, 2012...La Jolla Pharmaceutical Co., of San Diego, treated the last patient in the Phase I (Part A) portion of the Phase I/II trial of GCS-100 in patients with chronic kidney disease (CKD

Halozyme Therapeutics Inc., of San Diego, initiated a Phase II trial evaluating PEGPH20 as a first-line therapy for patients with Stage IV metastatic pancreatic cancer

Ceregene Inc., of San Diego, reported top-line data from its double-blind, randomized, controlled Phase IIb study of CERE-120 (AAV-neurturin), a gene therapy designed to deliver the neurotrophic factor neurturin, for Parkinson's disease

Arena Pharmaceuticals Inc., of San Diego, initiated dosing in a Phase I trial of APD334, an oral drug candidate targeting the sphingosine 1-phosphate subtype 1 receptor, for the potential treatment of autoimmune diseases

Aragon Pharmaceuticals Inc., of San Diego, dosed its first patient in a Phase I trial of ARN-810 for estrogen receptor-positive breast cancer...Vital Therapies Inc., of San Diego, enrolled the first patient in a Phase III trial designated VTI-208, a randomized, open-label, multicenter, controlled trial comparing the company's investigational bio-artificial liver support system, ELAD plus standard of care, vs

Neurocrine Biosciences Inc., of San Diego, said it started a Phase IIb trial testing elagolix, an oral gonadotropin-releasing hormone antagonist, in uterine fibroids

OncoSec Medical Inc., of San Diego, reported positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial of its ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors...Trius Therapeutics Inc., of San Diego, reported top-line results from its ESTABLISH 2 Phase III study of tedizolid phosphate (TR-701) in acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA

Upsher-Smith Laboratories Inc., of Maple Grove, Minn., presented data at the American Academy of Neurology meeting in San Diego, supporting favorable tolerability and a predictable, consistent pharmacokinetic profile of USL255 at high doses following single-dose administration to healthy subjects

Data were presented at the American Academy of Neurology meeting in San Diego...Data, presented at the American Academy of Neurology meeting in San Diego, indicated that Plegridy significantly reduced MS disease activity, including relapses, disability progression and brain lesions, compared to placebo at one year

Chelsea Therapeutics International Ltd., of Charlotte, N.C., said it will present results from Northera (droxidopa) Study 306 at the American Academy of Neurology 65th Annual Meeting, taking place March 16-23, in San Diego...Impax Pharmaceuticals, of Hayward, Calif., a division of Impax Laboratories Inc., disclosed the presentation of results from its Rytary (IPX066) Phase III and open-label extension trials at the 65th Annual Meeting of the American Academy of Neurology in San Diego on March 18

Santarus Inc., of San Diego, published results from its Phase III (CORE II) study of Uceris (budesonide) extended-release tablets for ulcerative colitis in the gut...Trevena Inc., King of Prussia, Pa., said that Phase I, first-in-man studies of TRV130 will be presented at the American Academy of Neurology meeting in San Diego, March 19

Ceregene Inc., of San Diego, said it completed enrollment in its Phase II study of CERE-110 (AAV-NGF), a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease

Lithera Inc., of San Diego, said the first patient was treated with LIPO-202 (salmeterol xinafoate for injection) in its 500-patient Phase IIb RESET trial

Endocyte Inc., of San Diego, said a new analysis demonstrated that the investigational diagnostic imaging agent etarfolatide (EC20) can identify ovarian cancer and non-small-cell lung cancer (NSCLC) patients who could benefit from folate receptor-targeted therapeutics, such as the investigational cancer candidate vintafolide (MK-8109/EC145...The results were presented at the first AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy in San Diego

Adventrx Pharmaceuticals Inc., of San Diego, began dosing patients in a QT/QTc study of ANX-188, an aqueous solution of purified poloxamer 188, to evaluate the effect of therapeutic and supra-therapeutic doses of the compound on cardiac ventricular repolarization in healthy volunteers

Genelux Corp., of San Diego, said researchers at Memorial Sloan Kettering Cancer Center in New York treated the first patient in a Phase I trial of GL-ONC1 in malignant pleural effusion, a complication that occurs in about 30 percent of lung cancers